Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Lipid Disorder Treatment Market 2020-2026

Published by Orion Market Research Pvt Ltd Product code 962274
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Lipid Disorder Treatment Market 2020-2026
Published: August 4, 2020 Content info:
Description

Global Lipid Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypercholesterolemia, Dysbetalipoproteinemia, Familial Combined Hyperlipidemia, and Others), By Product Type (Atorvastatin, Simvastatin, Pravastatin, Rosuvastatin, Lovastatin, and Other), By Distribution Channel (Hospital & Clinics, Retail Pharmacies, and Online Pharmacies), Forecast Period (2020-2026)

The global lipid disorder treatment market is anticipated to grow at a CAGR of 7.5% during the forecast period. Lipid disorder is a condition where patient's bodies either have high levels of low-density lipoprotein (LDL) cholesterol, triglycerides, or both. The diagnosis of lipid disorder is done by routine blood check-ups. The raising smoking and consumption of alcohol across the globe are driving the increasing cases of lipid disorder which in turn will fuel the lipid disorder treatment market.

The global lipid disorder treatment market is segmented based on the indication, product type, and distribution channel. Based on the indication, the market is sub-segmented into hypercholesterolemia, dysbetalipoproteinemia, familial combined hyperlipidemia, and others. Based on product type, the market is sub-divided into atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, and others. Further, based on the distribution channel, the market is sub-segmented into hospitals & clinics, retail pharmacies, and online pharmacies.

The global lipid disorder treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Asia Pacific is expected to show significant growth in the market during the forecast period. The growth in the region is owing to the growing cases of obesity and various other lifestyle disorders.

The key players of the global lipid disorder treatment market include Avanti Polar Lipids, ESPERION Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Micelle BioPharma, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market. For instance, in February 2019, Novartis AG has overtaken the responsibility of the development and commercialization of TQJ230 across the globe from Akcea Therapeutics.

Research Methodology

The market study of the global lipid disorder treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report is intended for the drug manufacturers, hospitals & clinics, insurance companies, government organizations, research institutes and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. Global Lipid Disorder Treatment Market Research and Analysis by Indication

2. Global Lipid Disorder Treatment Market Research and Analysis by Product Type

3. Global Lipid Disorder Treatment Market Research and Analysis by Distribution Channel.

The Report Covers:

Comprehensive research methodology of the global lipid disorder treatment market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global lipid disorder treatment market.

Insights about market determinants which are stimulating the global lipid disorder treatment market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents
Product Code: OMR2022176

Table of Contents

1. Report Summary

  • 1.1. Research Business Functions and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca Plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Ionis Pharmaceuticals, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Merck & Co. Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Novartis AG
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.1. Opportunities

5. Market Segmentation

  • 5.1. Global Lipid Disorder Treatment Market by Indication
    • 5.1.1. Hypercholesterolemia
    • 5.1.2. Dysbetalipoproteinemia
    • 5.1.3. Familial Combined Hyperlipidemia
    • 5.1.4. Others
  • 5.2. Global Lipid Disorder Treatment Market by Product Type
    • 5.2.1. Atorvastatin
    • 5.2.2. Simvastatin
    • 5.2.3. Pravastatin
    • 5.2.4. Rosuvastatin
    • 5.2.5. Lovastatin
    • 5.2.6. Other
  • 5.3. Global Lipid Disorder Treatment Market by Distribution Channel
    • 5.3.1. Hospital & Clinics
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Alnylam Pharmaceuticals, Inc.
  • 7.3. Amarin Corp.
  • 7.4. AstraZeneca Plc
  • 7.5. Avanti Polar Lipids, Inc.
  • 7.6. Cadila Healthcare Ltd.
  • 7.7. Eli Lilly and Co.
  • 7.8. ESPERION Therapeutics, Inc.
  • 7.9. Ionis Pharmaceuticals, Inc.
  • 7.10. Merck & Co. Inc.
  • 7.11. Micelle BioPharma, Inc.
  • 7.12. Moderna, Inc.
  • 7.13. Novartis AG
  • 7.14. Otsuka Pharmaceutical Co., Ltd.
  • 7.15. Pfizer Inc.
  • 7.16. Poxel SA
  • 7.17. Roivant Sciences Ltd.
  • 7.18. Sanofi SA
  • 7.19. Sumitomo Dainippon Pharma Co., Ltd
  • 7.20. Sun Pharmaceutical Industries Ltd.
  • 7.21. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 2. GLOBAL HYPERCHOLESTEROLEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL DYSBETALIPOPROTEINEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL FAMILIAL COMBINED HYPERLIPIDEMIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 7. GLOBAL ATORVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL SIMVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL PRAVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ROSUVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL LOVASTATIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 13. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
  • 14. GLOBAL HOSPITAL & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 15. GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 16. GLOBAL ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 17. GLOBAL LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 18. NORTH AMERICA LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. NORTH AMERICAN LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 20. NORTH AMERICAN LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
  • 21. NORTH AMERICAN LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 22. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 23. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 24. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
  • 25. EUROPE LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 26. ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 27. ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 28. ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
  • 29. ASIA PACIFIC LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)
  • 30. REST OF THE WORLD LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 31. REST OF THE WORLD LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
  • 32. REST OF THE WORLD LIPID DISORDER TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY INDICATION, 2019 VS 2026 (%)
  • 2. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY PRODUCT TYPE, 2019 VS 2026 (%)
  • 3. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2019 VS 2026 (%)
  • 4. GLOBAL LIPID DISORDER TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 5. US LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. CANADA LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. UK LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. FRANCE LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. GERMANY LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ITALY LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. SPAIN LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. ROE LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. INDIA LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. CHINA LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. JAPAN LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC LIPID DISORDER TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
Back to Top